| Literature DB >> 34629991 |
Abstract
Objective: To evaluate the myocardial protection of Ivabradine (IBD) combined with Trimetazidine (TMZ) in patients with coronary artery disease (CAD) after percutaneous coronary intervention (PCI), magnetic resonance imaging (MRI) images under convolutional neural network (CNN) algorithm were used.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34629991 PMCID: PMC8476248 DOI: 10.1155/2021/3150938
Source DB: PubMed Journal: Contrast Media Mol Imaging ISSN: 1555-4309 Impact factor: 3.161
Figure 1MRI image reconstruction based on neural network.
Figure 2Image reconstruction process of superresolution reconstruction algorithm.
Figure 3MRI images of patients with myocardial injury.
Figure 4CNN denoised MRI images.
Figure 5Analysis of diagnosis effect. Note. (a): the ROC curve; (b): the accuracy analysis result.
Contrast of clinical efficacy.
| Group | Significant effect ( | Effective ( | Ineffective ( | Effective rate (%) |
|---|---|---|---|---|
| IBD + TMZ | 20 | 15 | 5 | 87.50 |
| TMZ | 13 | 14 | 13 | 67.50 |
|
| - | 0.012 |
Contrast of left heart function before and after treatment between the two groups.
| Index | IBD + TMZ group | TMZ group | |
|---|---|---|---|
| LVEDD (mm) | Before | 61.97 ± 4.07 | 62.06 ± 3.95 |
| After | 40.88 ± 3.17 | 49.16 ± 3.42 | |
|
| |||
| LVEDV (mL) | Before | 112.97 ± 8.96 | 113.07 ± 9.42 |
| After | 91.14 ± 6.21 | 101.20 ± 7.04 | |
|
| |||
| LVESD (mm) | Before | 43.14 ± 3.86 | 42.88 ± 4.16 |
| After | 32.18 ± 3.51 | 37.62 ± 3.66 | |
|
| |||
| LVESV (mL) | Before | 65.21 ± 5.38 | 65.42 ± 5.69 |
| After | 40.91 ± 3.79 | 50.28 ± 4.42 | |
|
| |||
| LVEF (%) | Before | 41.08 ± 4.15 | 41.15 ± 4.50 |
| After | 54.83 ± 5.02 | 49.14 ± 4.93 | |
Note. In contrast to before treatment within group, P < 0.05; in contrast to TMZ group in the same period, #P < 0.05.
Contrast of cTnI, hs-CRP, MDA, and SOD before and after treatment.
| Index | IBD + TMZ group | TMZ group | |
|---|---|---|---|
| cTnI (ng/mL) | Before | 1.71 ± 0.26 | 1.70 ± 0.27 |
| After | 0.42 ± 0.05 | 0.97 ± 0.08 | |
|
| |||
| Hs-CRP (mg/L) | Before | 16.27 ± 1.73 | 16.31 ± 1.82 |
| After | 7.17 ± 0.42 | 11.50 ± 1.01 | |
|
| |||
| sICAM-1 (mg/L) | Before | 263.14 ± 36.63 | 259.37 ± 31.18 |
| After | 158.81 ± 21.55 | 216.59 ± 25.65 | |
|
| |||
| MDA ( | Before | 8.56 ± 1.16 | 8.53 ± 1.21 |
| After | 4.37 ± 0.38 | 6.83 ± 0.68 | |
|
| |||
| SOD (U/mL) | Before | 62.27 ± 5.97 | 63.17 ± 6.08 |
| After | 88.94 ± 9.17 | 71.26 ± 8.85 | |
|
| |||
| ET-1 (ng/L) | Before | 46.65 ± 6.22 | 47.06 ± 6.15 |
| After | 35.73 ± 5.82 | 43.08 ± 5.96 | |
Note. In contrast to before treatment within group, P < 0.05; in contrast to TMZ group in the same period, #P < 0.05.
Comparison of MACE occurrence.
| Group | Angina recurrence ( | ISR ( | Severe arrhythmia ( | Heart failure ( | Nonfatal myocardial infarction ( | Cumulative incidence (%) |
|---|---|---|---|---|---|---|
| IBD + TMZ | 5 | 3 | 1 | 0 | 1 | 25.00 |
| TMZ | 12 | 6 | 3 | 1 | 3 | 62.50 |
|
| — | 0.009 | ||||
6MWT and SAQ scores before and after treatment.
| Group | Period | 6MWT (m) | SAQ score |
|---|---|---|---|
| IBD + TMZ | Before | 195.78 ± 30.13 | 64.17 ± 8.06 |
| After | 389.81 ± 40.34 | 83.20 ± 8.79 | |
|
| |||
| TMZ | Before | 197.37 ± 31.94 | 64.08 ± 8.13 |
| After | 295.33 ± 32.17 | 93.05 ± 9.64 | |
Note. In contrast to before treatment within group, P < 0.05; in contrast to TMZ group in the same period, #P < 0.05.